<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Terziroli Beretta-Piccoli, Benedetta</dc:creator>
  <dc:creator>Mieli Vergani, Giorgina</dc:creator>
  <dc:creator>Vergani, Diego</dc:creator>
  <dc:date>2021-09-07</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Circulating autoantibodies are a key diagnostic tool in autoimmune hepatitis (AIH), being positive in 95% of the cases if  tested according to dedicated guidelines issued by the International Autoimmune Hepatitis Group. They also allow the  distinction between type 1 AIH, characterized by positive anti-nuclear and/or anti-smooth muscle antibody, and type 2 AIH,  characterized by positive anti-liver kidney microsomal type 1 and/or anti-liver cytosol type 1 antibody. Anti-soluble liver  antigen is the only AIH-specific autoantibody, and is found in 20–30% of both type 1 and type 2 AIH. Anti-neutrophil  cytoplasmic antibody is frequently positive in type 1 AIH, being associated also with inflammatory bowel disease and with  primary/autoimmune sclerosing cholangitis. The reference method for autoantibody testing remains indirect  immunofluorescence on triple tissue (rodent liver, kidney and stomach), allowing both the detection of the majority of liver- relevant reactivities, including those autoantibodies whose molecular target antigens are unknown. Of note, the current  knowledge of the clinical significance of autoantibodies relies on studies based on this technique. However,  immunofluorescence requires trained laboratory personnel, is observer-dependent, and lacks standardization, leading to  ongoing attempts at replacing this method with automated assays, the sensitivity, and specificity of which, however,  require further studies before they can be used as a reliable alternative to immunofluorescence; currently, they may be  used as complementary to immunofluorescence.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://localhost:5000/ark:/12658/srd1319281</dc:identifier>
  <dc:identifier>https://susi.usi.ch/global/documents/319281</dc:identifier>
  <dc:identifier>https://susi.usi.ch/documents/319281/files/TerziroliBeretta-Piccoli_crai_2021.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/s12016-021-08888-9</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/ark/12658/srd1319281</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>CC BY</dc:rights>
  <dc:source>Clinical reviews in allergy &amp; immunology. - Springer. - 2022, vol. 63, p. 124–137</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Autoimmune hepatitis</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Autoantibodies</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Indirect immunofluorescence</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Automated assays</dc:subject>
  <dc:subject>info:eu-repo/classification/udc/61</dc:subject>
  <dc:title xmlns:ns5="xml" ns5:lang="en">Autoimmune hepatitis : serum autoantibodies in clinical practice</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
